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Abstract  
 
Recent studies suggest that hippocampus has different cortical connectivity and functionality 
along its longitudinal axis. We sought to elucidate the possible different pattern of atrophy in 
longitudinal axis of hippocampus between Amyloid/Tau pathology and TDP-43-pathies.  
Seventy-three presenile subjects were included: Amyloid/Tau group (33 Alzheimer’s disease 
(AD) with confirmed CSF biomarkers), probable TDP-43 group (7 semantic variant 
progressive primary aphasia, 5 GRN and 2 C9orf72 mutation carriers) and 26 healthy 
controls. We conducted a region-of-interest voxel-based morphometry analysis on the 
hippocampal longitudinal axis, by contrasting the groups, covarying with CSF biomarkers 
(Aβ42, total tau, p-tau) and covarying with episodic memory scores. Amyloid/Tau pathology 
affected mainly posterior hippocampus while anterior left hippocampus was more atrophied 
in probable TDP-43pathies. We also observed a significant correlation of posterior 
hippocampal atrophy with AD CSF biomarkers and visual memory scores. Taken together, 
these data suggest that there is a potential differentiation along the hippocampal longitudinal 
axis based on the underlying pathology, which could be used as a potential biomarker to 
identify the underlying pathology in different neurodegenerative diseases. 
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1. Introduction 
The hippocampus has long been regarded as a homogenous structure, critically involved in 
episodic memory and disproportionate atrophy on structural MRI in medial, basal and lateral 
temporal lobe has been included as a neuronal injury biomarker for the pathophysiological 
process of Alzheimer’s disease (AD) in the diagnostic National Institute on Aging and 
Alzheimer's Association (NIA-AA) criteria (Albert et al., 2011; McKhann et al., 2011). This 
should be not surprising as the hippocampus is a medial temporal lobe structure critically 
involved in episodic memory and spatial navigation, which are some of the main symptoms 
in AD (Squire et al., 2004; Serino et al., 2014). Similarly, on a pathological level, amyloid 
and tau pathology converge in the medial temporal lobe in AD and have been strongly linked 
with the progression of the disease and clinical symptomology. It is therefore surprising to 
find that other proteinopathies (eg. frontotemporal dementia) have been shown to present at 
times with a similar degree of hippocampal atrophy than AD, despite different clinical 
presentations (Hornberger and Piguet, 2012; Irish et al., 2014, Ramanan et al., 2017). Indeed, 
behavioural variant frontotemporal dementia and semantic variant of primary progressive 
aphasia (svPPA) patients can show significant changes in the hippocampus (Hornberger et 
al., 2012; Chapleau et al., 2016). Importantly not all these dementias show significant 
episodic memory deficits, in particular svPPA patients present mainly deficits in semantic 
memory tasks while the other cognitive functions, such as non-verbal episodic memory and spatial 
navigation abilities are relatively more intact (Tan et al., 2014). This discrepancy suggests that 
the hippocampus might be not as homogenous in its function and vulnerability to different 
proteinopathies as previously thought.  
Recent data from healthy young humans, monkeys and rats suggest that there is a clear 
anatomical and functional differentiation of the hippocampus along its longitudinal axis 
(Poppenk and Moscovitch, 2011; Poppenk et al., 2013; Strange et al., 2014). The findings 
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suggest that the cortical connectivity of the anterior and posterior hippocampus might be 
different, suggesting that different cognitive specialisation might be harboured along the 
longitudinal axis of the hippocampus pending their cortical connectivity (Chase et al., 2015; 
Moscovitch et al., 2016). More specifically, Poppenk et al., suggest that anterior and 
posterior hippocampus connectivity to cortical networks bias them towards pattern 
completion and separation, respectively. Such functionality would be reflected in coarse, 
global representations in anterior hippocampus and fine-grained, local representations in 
posterior hippocampus (Poppenk et al., 2013). Such longitudinal differentiation of the 
hippocampus on an anatomical and functional level might have potentially significant 
implications for AD and related dementias. More specifically, for diagnostic purposes the 
hippocampusis seen more as a homogenous structure and hippocampal atrophy in putative 
ADis usually only established via visual inspection of more anterior hippocampus, with the 
posterior hippocampus rarely being considered (Scheltens et al., 1992). Even more 
concerning is the fact that the hippocampal long-axis and connected regions might be 
differentially affected across dementias or proteinopathies (eg. tau, amyloid, TDP-43), which 
is currently not taken into account diagnostically or for treatment outcome measures.  
The longitudinal axis differentiation in the hippocampus might explain the conundrum of 
why different dementias with hippocampal atrophy show varying degrees of episodic 
memory deficits. It would suggest that more posterior hippocampus is important for detailed 
episodic memory and spatial navigation and hence creating the symptomology in the patients. 
By contrast, more anterior hippocampal regions are less specific for episodic memory or 
indeed have a more global role in episodic or even semantic memory which does not cause 
clinically significant episodic memory problems (Zeidman and Maguire, 2016). A final 
important notion emerging from this is that therefore the longitudinal axis of the 
hippocampus might be more vulnerable to certain types of underlying protein pathology (eg. 
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amyloid, tau, TDP-43). Indeed, recent findings suggest that there is a distinct vulnerability of 
brain networks in Alzheimer’s disease, due to the interaction of amyloid and tau (Chetelat 
2013; Khan et al., 2014). Similarly, brain network vulnerability related to medial temporal 
lobe changes have also been observed in svPPA, which is mainly associated to TDP-43 
pathology (Snowden et al., 2007; Bejanin et al., 2017). However, few studies to date have 
specifically addressed whether the hippocampal long-axis might be differentially affected 
across such proteinopathies and how such a differentiation might relate to biomarkers and 
cognitive function (Barnes et al., 2006; Lindberg et al., 2017).  
In this study we address this shortcoming directly by investigating atrophy pattern in the 
longitudinal axis of the hippocampus in biomarker confirmed Amyloid/Tau and probable 
TDP-43 groups. We hypothesised that the longitudinal hippocampal axis would be i) 
differentially affected by proteinopathy status (Amyloid/Tau vs. probable TDP-43) with 
Amyloid/Tau affecting more posterior hippocampus and TDP-43 affecting more anterior 
hippocampus; ii) CSF tau and amyloid biomarkers would correlate more with posterior 
hippocampus; and iii) neuropsychological episodic memory scores would correlate more with 
posterior hippocampus.   
 
2. Material and methods 
2.1 Participants 
Seventy-three participants were retrospectively selected from the Early-onset Dementia 
Cohort and the Genetic counselling program for familial dementias (PICOGEN) both at the 
Alzheimer’s Disease and Other Cognitive Disorders Unit from Hospital Clinic Barcelona 
(Spain) including early-onset mild cognitive impairment (MCI) due to Alzheimer’s disease, 
early-onset AD (EOAD), svPPA, GRN and C9orf72 mutation carriers and age-matched 
healthy controls. The study protocol includes clinical and complete neuropsychological 
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evaluations, structural MRI, genetic markers and a spinal tap to determine CSF biomarkers. 
Diagnoses were established by an interdisciplinary clinical committee formed by neurologists 
and neuropsychologists. 
Global selection criteria were age at onset of symptoms <65 years and a score of 20 or above 
on the Mini Mental State Examination (MMSE). MCI patients showed impairment on one or 
more cognitive domains and had preserved activities of daily living, as measured by the 
Functional Activities Questionnaire (FAQ score <6; Pfeffer et al., 1982). All of them fulfilled 
NIA-AA clinical diagnostic criteria for MCI due to AD (Albert et al., 2011). AD patients 
fulfilled NIA-AA clinical diagnostic criteria for Dementia due to AD (McKhann et al., 2011) 
and they were in the mild stage of the disease (Global Deterioration Scale of 4). All MCI and 
AD patients had a typical AD CSF biomarkers profile in agreement with the internal values 
of our laboratory (Antonell et al., 2011). SvPPA patients met clinical diagnostic criteria for 
svPPA (Gorno-Tempini et al., 2011) and six of them had a normal AD CSF profile (only 1 
case had no information about amyloid status). Available symptomatic genetic 
frontotemporal lobar degeneration with predicted TDP-43 neuropathology were included:  
five GRN mutation carriers (three of them diagnosed as non-fluent variant of primary 
progressive aphasia (Gorno-Tempini et al., 2011) and two as behavioural variant of 
frontotemporal dementia (Rascovsky et al., 2011) and two C9orf72 mutations carriers, both 
with diagnosis of behavioural variant of frontotemporal dementia (Rascovsky et al., 2011). 
Three of genetic patients had normal AD CSF biomarkers profile (four cases had no 
information about amyloid status). Finally, healthy controls were recruited as research 
volunteers and defined as individuals with no cognitive complaints, no evidence of cognitive 
impairment in the neuropsychological tests and normal AD CSF biomarkers profile. 
Global exclusion criteria included prior history of mental illness, significant head injury, 
cerebrovascular disease or alcohol and other drug abuse. Disease duration was estimated as 
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the number of years elapsed since the reported onset of symptoms until participants 
underwent MRI.   
The participants were classified into three groups according to their predicted underlying 
neuropathology: 
 1. Amyloid/Tau Group (33 patients): this group included 18 early-onset MCI due to 
AD (14 single domain amnestic MCI and 4 multidomain amnestic MCI) and 15 EOAD.  
Because only the vast majority of the early-onset MCI who subsequently progressed to AD 
have a typical CSF biomarkers profile and EOAD patients are often misdiagnosed if the 
diagnosis is solely based on clinical data (Balasa et al., 2011, 2014), we only selected cases 
who according to NIA-AA diagnostic criteria have at least one amyloid positive biomarker 
(decreased Aβ42 CSF levels) plus one neuronal injury positive biomarker (increased total tau 
and/or phosphorylated tau (p-tau)
 
CSF levels). Thus, all our Amyloid/Tau Group patients met 
criteria to MCI due to AD with high likelihood or probable AD dementia with high evidence 
of the AD pathophysiological process (Albert et al., 2011; McKhann et al., 2011).  
 2. Probable TDP-43 group (14 patients): this group included patients with high 
probability of TDP-43 pathology, such as svPPA, and GRN or C9orf72 mutation carriers 
which in clinical-pathological correlation studies were mainly associated with TDP-43 
proteinopathy (Snowden et al., 2007, 2015). In nine patients concomitant AD pathology was 
excluded by normal AD CSF biomarkers.  
 3. Control group (26 healthy controls): we selected only healthy controls with a 
normal AD CSF biomarkers profile to exclude preclinical AD patients and possible structural 
changes which could be seen in this phase of the disease.   
A comprehensive neuropsychological battery was administered to all subjects by a trained 
neuropsychologist, including MMSE (Folstein et al., 1975), as a measure of global cognition 
and assessments of memory, executive functions, language, gnosis and praxis. Cognitive cut-
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off scores were defined taking into account the age and education of the patients, and were 
considered abnormal if they were more than 1.5 standard deviations below the mean. As we 
previously mentioned, the MMSE was used to select the patients. As our interest was to 
assess the correlation between hippocampal atrophy and different types of memory we 
selected the following tests for the correlational analysis: Free and Cued Selective Reminding 
Test (FCSRT) (Grober and Buschke, 1987) to assess episodic verbal memory and Landscape 
test (Valls-Pedret et al., 2011) and CERAD Constructional Praxis Recall (Fillenbaum et al., 
2011) to assess visual memory.  
 
2.2 APOE and biochemical CSF biomarkers 
The APOE genotype was determined using PCR amplification and the HhaI restriction 
enzyme.  
All the subjects underwent a spinal tap, during the morning. The samples were centrifuged 
and stored in polypropylene tubes at −80◦ C within 2 h. Levels of Aβ42, total tau, and p-tau 
were measured by experienced laboratory personnel using commercial sandwich ELISA kits 
(Fujirebio Europe, Gent, Belgium) 
  
2.3 Image acquisition and voxel-based morphometry (VBM) analysis 
All participants were examined on a 3T MRI scanner (Magnetom Trio Tim, Siemens Medical 
Systems, Germany) with the same imaging protocol. A high-resolution 3D structural data set 
(T1-weighted, MP-RAGE, repetition time = 2300 ms, echo time = 2.98 ms, 240 slices, field-
of-view = 256 mm, matrix size = 256x256, slice thickness = 1 mm) was acquired for all 
subjects. 
3D T1-weighted sequences were analysed using FSL-VBM, a voxel-based morphometry 
analysis (Ashburner and Friston, 2000; Good et al., 2001), which is part of the FSL software 
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package http://www.fmrib.ox.ac.uk/fsl/fslvbm/index.html (Smith et al., 2004). Following 
brain extraction, tissue segmentation was carried out using FMRIB’s Automatic 
Segmentation Tool (FAST) (Zhang et al., 2001). The resulting grey matter partial volume 
maps were aligned to the MNI standard space (MNI52) using the nonlinear registration 
approach with FNIRT (Anderson et al., 2007a, 2007b), which uses a b-spline representation 
of the registration warp field (Rueckert et al., 1999). To correct for local expansion or 
contraction, the registered partial volume maps were modulated by dividing them by the 
Jacobian of the warp field. Importantly, the Jacobian modulation step did not include the 
affine part of the registration, which means that the data was normalized for head size as a 
scaling effect. The modulated images were then smoothed with an isotropic Gaussian kernel 
with a standard deviation of 3 mm (FWHM: 8mm).  
First of all, a voxel-wise general linear model was applied to investigate differences in whole 
brain grey matter intensity between groups via permutation-based non-parametric testing 
(Nichols and Holmes, 2002) with 5000 permutations per contrast. Then, given our selected 
hypothesis we created regions of interest for the anterior and posterior hippocampus by 
including the first and last third of the hippocampus for the left and right hemispheres. The 
mask was created based on the Harvard-Oxford probabilistic atlas for the hippocampus. 
There are currently no clear guidelines as to what constitutes anterior and posterior 
hippocampus, so the mask was simply divided in thirds manually to define anterior and 
posterior; therefore our approach was to be quite conservative by only including the most 
anterior and posterior thirds of the HC.  A voxel-wise general linear model was applied to 
investigate differences in grey matter intensity via permutation-based non-parametric testing 
(Nichols and Holmes, 2002) with 500 permutations per contrast. As a first step, differences in 
hippocampal grey matter intensity between groups (Amyloid/Tau group and probable TDP-
43 group) and controls were assessed. Group comparisons between groups and controls were 
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tested for significance at p <.01, corrected for multiple comparisons via Family-wise Error 
(FWE) correction across space. A cluster extent threshold of 20 contiguous voxels was 
applied for group comparisons.  
Next, correlations between different CSF biomarkers (t-tau, p-tau and Aβ42) and performance 
on 3 memory tests (FCSRT, Landscape test and CERAD Constructional Praxis Recall) and 
regions of hippocampal grey matter atrophy were investigated in patients combined with 
controls. This procedure has previously been used in other studies (Irish et al., 2014) to detect 
brain-behavioural relationships, and serves to achieve greater variance in difference scores, 
thereby increasing the statistical power. Here we apply this methodology to detect 
hippocampal-cognitive relationships. Furthermore, in the CSF correlation analyses as groups 
were constituted on the basis of positive (Amyloid/Tau group) versus negative (probable 
TDP-43 group and controls) biomarkers, we also analysed the correlations between different 
CSF biomarkers and regions of hippocampal grey matter atrophy in each group alone.  For 
statistical power, a covariate only statistical model with a [1] t-contrast was used, providing 
an index of association between grey matter intensity and performance on cognitive test. All 
correlations between CSF biomarkers and cognitive test and hippocampal atrophy were tested 
for significance at p <.01 or p <.05, corrected for multiple comparisons via FWE correction 
across space. The same cluster extent threshold of 20 contiguous voxels was applied for these 
correlations. 
Anatomical locations of significant results were overlaid on the MNI standard brain, with 
maximum coordinates provided in MNI stereotaxic space.  
 
2.4 Statistical analysis 
Demographic, cognitive, genetic and CSF biomarkers characteristics are reported as means 
and standard deviations or proportions when appropriate. Data were analysed using SPSS 
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22.0 (IBM, Chicago, Ill., USA). Kolmogorov-Smirnov tests were used to check for normality 
of distribution. Normally distributed scores were compared across groups using ANOVAs. 
Non-normally distributed scores were compared across groups using Kruskal-Wallis tests. 
When significant differences were detected a Mann-Whitney U test was used to compare 
specific groups. Chi-squared test was used to compare sex and APOE distribution across 
groups.  
 
2.5 Ethics statement 
All participants gave written informed consent. The study was approved by the Hospital 
Clinic Barcelona Ethics Committee and carried out in compliance with the ethical standards 
laid down in the 1964 Declaration of Helsinki and its later amendments. 
 
3. Results 
3.1 Demographics, cognition, APOE and CSF biomarkers 
Demographics, neuropsychological data, APOE genotype and CSF biomarkers for the 
different groups are displayed in Table 1. There were no significant differences between 
groups in age and sex. Additionally, patient groups were as well matched for disease 
duration. 
APOE 4 was more frequent in the Amyloid/Tau group compared to the probable TDP-43 
group and controls (p<0.05), but no differences were found between the probable TDP-43 
group and controls. 
Neuropsychological testing revealed cognitive differences between groups (Table 1). Briefly, 
both patient groups were impaired compared to controls on MMSE (p < 0.05), but did not 
differ significantly from each other. In both patient groups, impairments were also observed 
on FCSRT, Landscape test and CERAD Constructional Praxis Recall (all p values < 0.05) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12                              
 
compared to controls. Direct comparison between the two patient groups displayed more 
impairment on Landscape test and CERAD Constructional Praxis Recall (p values < 0.05) in 
the Amyloid/Tau group, but there was no difference in FCSRT.   
As expected from the selection criteria all AD CSF biomarkers were significantly altered in 
Amyloid/Tau group compared with probable TDP-43 group and controls (p< 0.001).  
 
3.2 Voxel-based morphometry results 
3.2.1 Group comparisons 
Compared to controls, Amyloid/Tau group and probable TDP-43 group showed extensive 
atrophy including frontal, temporal, parietal and occipital regions (Supplementary Figure 1A 
and 1B). Direct comparison of the Amyloid/Tau and probable TDP-43 groups revealed 
greater atrophy in the precuneus in Amyloid/Tau group (Supplementary Figure 1C). The 
reverse contrast revealed greater atrophy in the left anterior temporal lobe, extending into 
inferior frontal and ventromedial prefrontal cortices in the probable TDP-43 group 
(Supplementary Figure 1D). 
Compared to controls, Amyloid/Tau group showed atrophy in anterior and posterior 
hippocampus bilaterally, although this atrophy was more extended in the posterior regions 
(Figure 1A and Table 2).  
Compared to controls, the probable TDP-43 group showed atrophy in the anterior and 
posterior left hippocampus but only in the anterior region of the right hippocampus (Figure 
1B, Table 2). Finally, direct comparison of the Amyloid/Tau and probable TDP-43 groups 
revealed greater atrophy in the right posterior hippocampus in Amyloid/Tau group (Figure 
1C: Table 2 and 3). The reverse contrast revealed greater atrophy in the left anterior 
hippocampus in the probable TDP-43 group (Figure 1C: Table 2 and 3).  
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3.2.2 CSF biomarker correlations 
In whole sample AD CSF biomarkers were correlated with the atrophy of posterior regions of 
the hippocampus.  More specifically, total tau was correlated with the posterior left side 
(Figure 2A, table 4) and p-tau and Aβ42 with the posterior hippocampus bilaterally (Figure 2B 
and 2C, table 4). However, when we analysed the correlations between different CSF 
biomarkers and regions of hippocampal grey matter atrophy in each group to separate we 
found no correlations.  
 
3.2.3 Cognitive correlations 
Immediate free recall and delayed free recall of FCSRT were correlated with atrophy 
involving all analysed regions of the hippocampus (i.e., anterior and posterior), although the 
atrophy was more extensive in the posterior regions (Figure 3A and 3B, Table 5). Immediate 
total recall and delayed total recall scores of FCSRT were correlated with atrophy involving 
bilateral posterior hippocampus and anterior left hippocampus (Table 5). The Landscape test 
was associated with bilateral posterior hippocampus (Figure 3C, Table 5), whereas we only 
detected atrophy in left posterior hippocampus associated with CERAD Constructional Praxis 
Recall (Figure 3D, Table 5). 
In a post-hoc analysis, we explored whether any cognitive measure would be more related to 
the anterior hippocampal atrophy. The rationale for this analysis was to explore if we can also 
observe a cognitive differentiation across the longitudinal axis. To this purpose we correlated 
the total score of the Boston Naming Test (BNT), a semantic language test, with hippocampal 
atrophy. The results showed that a low score in BNT was clearly associated with greater 
anterior left hippocampal atrophy (Supplementary Figure 2, Supplementary Table 1).   
 
4. Discussion 
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The aim of the current study was to assess hippocampal atrophy along its longitudinal axis as 
a function of different underlying pathologies. Our results clearly show that AD 
(Amyloid/Tau group) affects anterior and posterior hippocampus with a clear emphasis on the 
posterior hippocampus. By contrast, probable TDP-43pathies mainly showed anterior HC 
changes. In addition, atrophy correlations with cognitive tests showed that visual memory 
(Landscape test and CERAD Constructional Praxis Recall) correlated with posterior 
hippocampus, whereas verbal memory (FCSRT) correlated with both anterior and posterior 
hippocampal atrophy. More importantly, we also observed a correlation between posterior 
hippocampal atrophy and CSF AD biomarker levels. Taken together, these data suggest that 
there is a potential differentiation along the hippocampal longitudinal axis based on the 
underlying pathology.  
To our knowledge, there are few studies to explore exclusively the pattern of hippocampal 
atrophy along its longitudinal axis in biomarker confirmed AD, probable TDP-43pathies and 
controls using VBM analysis. In a previous study by volumetric magnetic resonance imaging, 
Chan et al., (Chan et al., 2001a) described a marked difference in the distribution of temporal 
lobe atrophy between svPPA and AD. Similar to our data they found an anteroposterior 
gradient in the distribution of temporal lobe atrophy, with more marked atrophy anteriorly, in 
svPPA. However, in AD there was symmetrical atrophy of the entorhinal cortex, 
hippocampus, and amygdala, with no evidence of an anteroposterior gradient in the 
distribution of temporal lobe or hippocampal atrophy.  These differences with our results 
could be explained by a different used methodology and a lower number of AD patients 
evaluated without biological AD confirmation. In another different approach Lindberg et al., 
have conducted shape analysis of hippocampus on clinically diagnosed dementia patients and 
controls. They found more atrophy in left hippocampal body with relative sparing of the 
hippocampal head in AD. On the other hand, in the same study, compared to controls, svPPA 
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displayed severe atrophy of the whole left hippocampus, although in concordance to our data, 
they found, more limited posterior pathology in milder cases (Lindberg et al., 2012). Our 
findings also are in concordance to data from a study based on pathologically confirmed 
cases, which Barnes et al. show more pronounced atrophy of the anterior than posterior part 
of hippocampus in svPPA compared to controls in a volumetric magnetic resonance imaging 
(Barnes et al., 2006). 
Our findings fit well with the framework proposed by Ranganath and Ritchey (Ranganath 
and Ritchey, 2012), based on anatomic and functional data from humans, monkeys and rats, 
which hypothesises that the hippocampus is involved in two cortical systems that harbor 
different cognitive/memory functions. On the one hand, the posterior medial system which 
includes regions more implicated in AD such the parahippocampal cortex, retrosplenial 
cortex, anterior thalamic nuclei, mammillary bodies, pre- and parasubiculum and components 
of the default mode network (including the posterior cingulate, precuneus, angular gyrus and 
ventromedial prefrontal cortex) is clearly linked to the posterior hippocampus. On the other 
hand, the anterior-temporal system, including the perirhinal cortex, temporopolar cortex, 
lateral orbitofrontal cortex and amygdala, would be particularly connected to the anterior 
hippocampus (Ranganath and Ritchey, 2012; Aggleton, 2012; Poppenk et al., 2013). In 
concordance with our data these two cortical systems would mainly be differently affected by 
different disease/proteinopathies. More specifically and also in concordance to our findings in 
whole brain patterns of atrophy between groups the posterior medial system should be more 
vulnerable to Alzheimer´s disease pathophysiology whereas the anterior temporal system 
would be more vulnerable to TDP-43 pathologies such as svPPA, behavioural variant of 
frontotemporal dementia and Amyotrophic lateral sclerosis-Frontotemporal dementia. This 
hypothesis is also in concordance with the disproportionate atrophy of the anterior 
hippocampus in svPPA (Chan et al., 2001b; Chapleau et al., 2016) and the fact that AD and 
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svPPA differentially affect brain metabolism (La Joie et al., 2014). Interestingly, there is a 
strong similarity between brain regions specifically affected in AD and svPPA and brain 
regions that are specifically connected with the posterior versus anterior hippocampus 
respectively (La Joie et al., 2014). The clear correlation between all AD CSF biomarkers with 
atrophy of posterior regions of hippocampus also suggests that these regions would be more 
vulnerable to Amyloid/Tau pathology. Similar to our data, Lindberg et al. found elevated p-tau 
and low Aβ42 levels in CSF are mostly associated with the volume changes of the posterior subiculum, 
a subfield of the hippocampus, in 302 cognitively normal elderly participants, 183 patients with 
subjective cognitive decline and 171 patients with amnestic MCI (Lindberg et al., 2017).  
Our data also nicely dovetails with the different patterns of cognitive deficits reported in AD 
and svPPA. More specifically, the hallmark symptoms of episodic memory and spatial 
navigation are more clearly related to posterior hippocampal regions. This is particularly true 
for visual memory tests such as the Landscape tests and CERAD Constructional Praxis 
Recall, which require a high degree of detail to correctly recall. Interestingly, the verbal recall 
test (FCSRT) correlated with both anterior and posterior hippocampus, suggesting that the 
verbal nature and more reliance on semantics relies also on anterior hippocampal regions. 
This fits nicely with current models of episodic memory and also links with theoretical 
models suggesting that the anterior hippocampus is more related to broader or generic 
information retrieval than posterior regions which allow a higher degree of details (Maguire 
and Mullally, 2013; Zeidman and Maguire, 2016; Moscovitch et al., 2016). In concordance to 
our data, Lindberg et al. also described mild memory dysfunction was mostly associated with 
the volume changes of the posterior subiculum (Lindberg et al., 2017).  We further explored 
this notion in a post-hoc analysis showing that a semantic test (BNT) correlated exclusively 
with anterior left hippocampal atrophy. The post-hoc findings also relate to the clinical 
symptomatology of many TDP-43pathies, which show varying degrees of semantic 
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impairment and concomitant anterior hippocampus changes (Hornberger et al., 2012; Yew et 
al., 2013). Clinically, these findings suggest that the reliance of verbal episodic memory tests 
might not be advisable as they are not specific underlying pathology, in contrast to more 
visual episodic memory tests. 
In terms of the pathology, it is interesting that these different anterior and posterior 
hippocampal networks should be differentially susceptible to the underlying pathology. Our 
findings could seem contradictories to neuropathological studies that have shown that the 
earliest site of cortical tau-pathology is in the transentorhinal and then entorhinal cortex, 
which is adjacent to the anterior part of the hippocampus (Braak and Braak, 1991) and studies 
in preclinical patients that have also shown that the lateral entorhinal cortex and the anterior 
hippocampal system is earliest affected by AD-pathology (Khan et al., 2014). Indeed, the 
entorhinal cortex is located closer to anterior hippocampus and it is therefore not clear why 
posterior hippocampus would be more affected in AD. One speculation is that the anatomical 
connectivity of the entorhinal cortex is actually very strong with the retrosplenial cortex and 
posterior hippocampus (Vann et al., 2009). Therefore posterior regions might be more 
vulnerable than anterior hippocampus. Still, this remains clearly speculation for now, 
however a very recent study indicates indeed such a pattern (Jacobs et al., 2018). 
Nevertheless, this clearly needs to be further investigated in the future.  Indeed such 
pathological vulnerability for different hippocampal regions could have significant 
implications for dementia diagnosis and its specific therapeutic approaches. Specifically, 
which hippocampal regions should be employed for best diagnostic and treatment outcome 
measures? Based on our results, we suggest that the hippocampal long-axis affectation could 
be used as a potential biomarker to identify the underlying pathology (tau, TDP-43) which to 
date is still highly controversial. Indeed, in particular for behavioural variant of 
frontotemporal dementia patients who usually have a 50:50 distribution of underlying tau and 
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TDP-43 pathology (Mackenzie et al., 2010) this would be highly informative, as current 
intervention trials cannot determine the underlying pathology in those cases. Still, it would be 
somewhat ironic if the longitudinal axis of the hippocampus would emerge as potential 
imaging biomarker for behavioural variant of frontotemporal dementia, as hippocampal 
atrophy and associated episodic memory are still seen as quite controversial and might even 
preclude a diagnosis of behavioural variant of frontotemporal dementia (Rascovsky et al., 
2011). The current findings might overcome this problem by showing that behavioural 
variant of frontotemporal dementia patients can have hippocampal atrophy in particular 
anteriorly due to TDP-43 pathology and virtually no visual episodic memory problems, 
whereas those with tau pathology will have more posterior hippocampal atrophy and episodic 
memory problems. Indeed, recent controversial findings showing that a subgroup of 
behavioural variant of frontotemporal dementia patients might have episodic memory 
problems (Hornberger et al. 2010; Bertoux et al. 2014) would be indicative of underlying tau 
pathology, although this clearly needs to be investigated further in the future.  
Despite these promising findings, a number of methodological issues in our study warrant 
consideration. Firstly, given that our patients had not yet pathological confirmation, we 
cannot definitively confirm the underlying disease pathology in each group, although it is 
unlikely due to the availability and confirmation via biomarkers. A second limitation of this 
study concerns the age of the patients. All of them have early-onset dementia and we cannot 
ensure that the pathophysiological process in these cases is the same as in late-onset 
dementia. However, we selected this sample to avoid the overlap of different pathologies 
present in many late-onset cases. Finally, this was a retrospective study, and therefore some 
of the cognitive and biomarker data were not available for some participants.  
 
5. Conclusion 
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Our results show that Amyloid/Tau pathologies affected mainly posterior hippocampus while 
that anterior hippocampus is more atrophied in TDP-43pathies. These specific hippocampal 
long-axis affectations have also specific cognitive and biomarker correlations. We also 
suggest that this differentially hippocampal impact could be used as a potential biomarker to 
identify the underlying pathology in different neurodegenerative diseases. For the future, it 
would be important to corroborate our findings and also investigate whether such longitudinal 
specific changes might improve disease detection at a presymptomatic stage of the 
investigated pathologies. 
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Figure legends 
 
Figure 1: VBM analysis showing hippocampal regions of significant grey matter intensity 
decrease between (A) Amyloid/Tau group vs healthy controls, (B) probable TDP-43 group vs 
healthy controls (C) Amyloid/Tau group and probable TDP-43 group. In (C) red voxels show 
regions that were greater atrophied in Amyloid/Tau group and Blue voxels regions that were 
greater atrophied in probable TDP-43 group. The voxels of hippocampal mask without 
significant differences between groups were shown in white. All results were significant in 
the analysis with p < 0.01 corrected with a cluster threshold of 20 contiguous voxels. Clusters 
are overlaid on the MNI standard brain. 
 
Figure 2: VBM results showing hippocampal regions of significant grey matter intensity 
decrease which correlate with total tau (negative correlation) (A), p-tau (negative correlation) 
(B) and Aβ42 (positive correlation) (C) in the CSF analysis. As described in methods, 
correlations between different CSF biomarkers and regions of hippocampal grey matter 
atrophy were investigated in patients combined with controls (n=68). The voxels of 
hippocampal mask without significant differences between groups were shown in white. All 
results were significant in the analysis with p < 0.05 corrected with a cluster threshold of 20 
contiguous voxels. Clusters are overlaid on the MNI standard brain. 
 
 
Figure 3: VBM results showing hippocampal regions of significant grey matter intensity 
decrease which correlate with different memory test: FCSRT-IFR: FCSRT-Immediate Free 
Recall (A), FCSRT-DFR: FCSRT-Delayed Free Recall (B), Landscape test (C) and CERAD 
Constructional Praxis Recall (D). As described in methods, correlations between FCSRT 
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(n=64), Landscape test (n=60) and CERAD Constructional Praxis Recall (n=43) and regions 
of hippocampal grey matter atrophy were investigated in patients combined with controls. 
The voxels of hippocampal mask without significant differences between groups were shown 
in white. FCSRT-IFR and FCSRT-DFR were significant in the analysis with p < 0.01 
corrected and Landscape test and CERAD Constructional Praxis Recall were significant in 
the analysis with p < 0.05 corrected. All shown cluster have a threshold of 20 contiguous 
voxels. Clusters are overlaid on the MNI standard brain. 
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Supplementary material 
 
Supplementary Table 1: VBM results showing hippocampal regions of significant grey 
matter intensity decrease which correlate with Boston Naming Test score. 
 
Supplementary Figure 1: 
VBM analysis showing regions of significant grey matter intensity decrease in the whole 
brain between (A) Amyloid/Tau group vs healthy controls, (B) probable TDP-43 group vs 
healthy controls (C) Amyloid/Tau group vs probable TDP-43 group and (D) probable TDP-
43 group vs Amyloid/Tau group. Results were significant in the analysis with p < 0.01 
corrected in A, B and D. Results were significant in the analysis with p < 0.05 corrected in C. 
Clusters are overlaid on the MNI standard brain. 
 
Supplementary Figure 2: 
VBM results showing hippocampal regions of significant grey matter intensity decrease 
which correlate with Boston Naming Test score. This result was significant in the analysis 
with p < 0.01 corrected. All shown cluster have a threshold of 20 contiguous voxels. Clusters 
are overlaid on the MNI standard brain. The voxels of hippocampal mask without significant 
differences between groups were shown in white. 
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Table 1. Demographic characteristics, cognition data, APOE genotype and CSF 
biomarkers for different groups and controls. 
 
Parameters Amyloid/Tau group 
n=33 
Probable TDP-
43 group 
n=14 
Healthy Controls 
n=26 
Gender (male/Female)  14/19 7/7 6/20 
Age (years) 59.7±4.5 58.4±4.8 57.6±3.9 
Disease duration (years) 2.8±1.2 2.7±2.3 NA 
MMSE 24.3±2.6 f 25.9±3.3 i 28.9±1.1 
FCSRT-Immediate Free Recalla 7.5±5.1 f 10.5±10.7 i 29.5±6.0 
FCSRT-Immediate Total Recalla 19±10.9 f 17.0±16.5 i 44.0±4.0 
FCSRT-Delayed Free Recalla 2.1±2.3 f 4.6±5.1 i 11.7±2.3 
FCSRT-Delayed Total Recall a 5.6±4.3 f 6.3±6.6 i 14.9±1.6 
Landscape testb  37.2±6.2 f,h 42.1±4.7 i 46.5±3.2 
CERAD Constructional Praxis 
Recall c  
3.2±2.9 f,h 7.0±3.2 i 10.3±0.7 
APOEd 63.3% f,h 8.3% 26.9% 
Aβ42 e 396.0±93 f,h 802.4±186.8 845.5±223.4 
Total-taue 842.6±460.9 f,h 305.3±133.4 i 218.1±49.1 
P-taue 114.7±37.1 f,h 43.3±11.8 50.6±10.5 
 
All values are displayed as mean ± standard deviation or proportionThe CSF biomarkers 
values are expressed in pg/ml. 
a Data missing for 9 subjects (3 from Amyloid/Tau Group, 4 from probable TDP43 
group and 2 from Healthy Control group) 
b Data missing for 13 subjects (4 from Amyloid/Tau Group, 5 from probable TDP43 
group and 4 from Healthy Control group) 
c
 Data missing for 30 subjects (13 from Amyloid/Tau Group, 11 from probable TDP43 
group and 6 from Healthy Control group) 
d
 Data missing for 3 subjects (all of them from the probable TDP43 group) 
e Data missing for 5 subjects (all of them from the probable TDP43 group) 
f
 Significant differences between AD group and control group (P values < 0.05). 
h Significant differences between AD group and  probable TDP43 group (P values < 
0.05). 
i  Significant differences between probable TDP-43 group and control group (P values < 
0.05). 
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Table 2. Voxel-based morphometry results showing hippocampal regions of significant 
grey matter intensity decrease between different patient groups and healthy controls. 
 
Contrast Regions Hemisphere 
MNI Number of 
voxels T z-score x y z 
Amyloid/Tau group 
vs healthy controls * 
Posterior Right 27 47 31 234 2.8961 
Posterior Left 57 46 31 202 2.8961 
Anterior Right 30 59 23 171 2.8961 
Anterior Left 59 60 22 41 2.6459 
Probable TDP43 
group         vs 
healthy controls * 
Anterior Left 57 59 21 276 2.8961 
Anterior Right 30 60 23 117 2.8961 
Posterior Left 56 46 31 99 2.8961 
Amyloid/Tau group 
vs probable TDP-43 
group* 
Posterior Right 30 48 31 82 2.3793 
Probable TDP-43 
group         vs  
Amyloid/Tau group* 
Anterior Left 57 59 21 253 2.8961 
 
*
 Results corrected at P < 0.01; only clusters with at least 20 contiguous voxels 
included. MNI=Montreal Neurological Institute.  
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Table 3. Qualitative summary of patterns of hippocampal atrophy 
along its longitudinal axis between patient groups. 
 
Hemisphere Segment 
Amyloid/Tau group 
vs  probable TDP-43 
group 
Probable TDP-43 
group vs 
Amyloid/Tau group 
Right 
Anterior 
Hippocampus - - 
Posterior 
Hippocampus ↓ - 
Left 
Anterior 
Hippocampus - ↓↓ 
Posterior 
Hippocampus - - 
 
 
All results are corrected at P < 0.01 
↓: cluster size smaller than 100 voxels  
↓↓: cluster size bigger than 200 voxels  
-: No significative difference between groups. 
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Table 4. Voxel-based morphometry results showing hippocampal regions of 
significant grey matter intensity decrease which correlate with different CSF AD 
biomarkers.  
 
Parameters Regions Hemisphere  MNI 
x        y         z 
Number  of 
voxels 
T z-score 
Total tau CSF* Posterior Left 56 47 33 78 1.9935 
P-tau CSF* 
Posterior Left 56 47 33 65 1.6663 
Posterior Right 34 43 38 46 1.6663 
Aβ42 CSF* 
Posterior Right 30 43 36 136 2.3793 
Posterior Left 56 47 33 37 1.9935 
 
*
 Results corrected at P<0.05. Only clusters with at least 20 contiguous voxels included. 
MNI+Montreal Neurological Institute. 
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Table 5. Voxel-based morphometry results showing hippocampal regions of significant grey matter 
intensity decrease which correlate with different cognitive test. 
 
Parameters Regions Hemisphere  MNI 
 x              y            z 
Number  
of voxels 
T z-
score 
FCSRT-Immediate 
Free Recall*  
Posterior Right 31 47 30 196 2.8961 
Posterior Left 58 45 31 191 2.8961 
Anterior Left 57 59 21 100 2.8961 
Anterior Right 30 61 23 27 2.8961 
FCSRT-Immediate 
Total Recall*  
Posterior Left 58 45 31 192 2.8961 
Posterior Right 33 48 31 191 2.8961 
Anterior Left 57 59 21 174 2.8961 
FCSRT-Delayed 
Free Recall*  
Posterior Right 31 47 30 209 2.8961 
Posterior Left 58 45 31 198 2.8961 
Anterior Left 58 59 21 81 2.8961 
Anterior Right 30 61 23 29 2.6459 
FCSRT-Delayed 
Total Recall*  
Posterior Left 58 45 31 189 2.8961 
Posterior Right 28 45 34 162 2.8961 
Anterior Left 58 60 22 69 2.8961 
Landscape Test**  
Posterior Right 27 46 32 78 1.6663 
Posterior Left 57 47 32 77 1.9935 
CERAD 
Constructional 
Praxis Recall ** 
Posterior Left 57 47 33 127 2.3793 
 
*
 Results corrected at P < 0.01 or **P<0.05; only clusters with at least 20 contiguous voxels 
included. MNI+Montreal Neurological Institute. 
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Highlights  
 
• Hippocampus could have distinct vulnerability to different proteinopathies.  
• Amyloid/Tau pathology affected mainly posterior hippocampus.  
• Anterior left hippocampus was more atrophied in TDP-43pathies. 
• Visual memory scores correlated with posterior hippocampal atrophy. 
• The hippocampal atrophy pattern (longitudinal axis) could be a new biomarker. 
 
 
